SGLT2 inhibitors for heart failure patients during ventilator weaning
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a heart failure medication (SGLT2 inhibitor) to help people with heart failure who are on a breathing machine (ventilator) get better and come off the machine faster. It is for patients with a specific type of heart failure where the heart pumps weakly (EF ≤ 40%).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 20 years or older
- You are in the hospital for heart failure and your heart's pumping strength is 40% or less (called HFrEF)
- You must be on a breathing machine and meet certain stable vital sign and medication criteria before starting the study drug
- Your NT-proBNP or BNP lab test must be high (a sign of heart strain), with higher levels if you have atrial fibrillation
- You cannot have certain medical conditions like recent heart attack, stroke, or severe kidney disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called enavogliflozin (an SGLT2 inhibitor) to see if it helps people with a specific type of heart failure where the heart pumps normally but is stiff. You may be able to join if you have stable heart failure, are not on another SGLT2 inhibitor, and have good kidney function.
This Phase 3 trial tests whether starting an SGLT2 inhibitor early in the hospital can improve outcomes for people at high risk after acute (sudden) heart failure. If you qualify, you would be randomized to receive the study medicine or standard care, started within 12 hours of admission.
This trial tests whether a type of diabetes medicine called SGLT2 inhibitors can lower inflammation and stress markers in people with heart failure. It may help reduce damage to the heart and improve symptoms.
This trial studies whether starting an SGLT-2 inhibitor around the time of a heart attack can reduce heart damage size and improve how the heart heals. It focuses on people with a high risk of developing heart failure and who are getting a procedure to open blocked heart arteries.
This study tests if a heart medication called levosimendan helps people get off the breathing machine (ventilator) faster. It's for people who have been on a ventilator for more than 48 hours and have already tried and failed to breathe on their own.
This trial tests two medications (finerenone and SGLT2 inhibitors) together in heart failure. It aims to see if the combination works better than either alone.
Hear when a new Ventilator Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.